Cancer is one of the leading causes of death worldwide. According to the World Health Organization, about 8.2 million deaths occurred in 2012 due to cancer. The most common kinds of cancer which tend to result in death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and oesophageal cancer. Apart from the mature chemotherapy market, biotherapy has emerged as a new approach for cancer treatment. Biotherapy boosts the body’s immune system to slow or stop the growth of cancer cells. Growing demand for personalized medicine and the introduction of novel approaches are expected to drive the market growth. Astra Zeneca PLC, Biogen IDEC, Bristol-Myers Squibb, Sanofi, Merck, Johnson & Johnson, Schering-Plough and Roche are some players in this market.
The cancer therapeutics and biotherapeutic market is segmented into technology and geography. On the basis of technology, the market is segmented into Chemotherapy, radiation therapy, hormonal therapy and biotherapy. Chemotherapy includes alkylating agents, cytotoxic agents, antimetabolites, plant derivatives and others. Radiation therapy comprises of Intraoperative radiotherapy, external beam radiation therapy, brachytherapy and radioisotope therapy. Hormonal therapy consists of hormone antagonists, corticosteroids, aromatase inhibitors, and selective estrogen receptor modulators (SERMs.) Biotherapy includes monoclonal antibodies, interleukins, kinases and others. Geographically, the market is segmented into North America, Europe, Asia-Pacific and LAMEA.
Key Market Segments
Market by Technology
Market by Geography